Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Diabetes is associated with an increased risk for developing premature macrovascular
complications. The process of irreversible subclinical damage to the vasculature already
starts during its preceding stages. Dipeptidyl peptidase (DPP)-4 inhibitors have been shown
to attenuate vascular damage in preclinical studies. Off-target effects on adipose tissue
inflammation, liver steatosis and atherosclerotic plaques have been extensively documented in
animal studies.
Based on these considerations the investigators hypothesize that early therapy with the DPP4
inhibitor linagliptin in subjects with treatment naive type 2 diabetes will lead to
beneficial effects on arterial stiffness as measured by pulse wave velocity.